Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis

• Published in: Oncotarget Vol. 7; no. 19; pp. 28139 - 28150
• Main Authors: Volpato, Milene, Perry, Sarah L, Marston, Gemma, Ingram, Nicola, Cockbain, Andrew J, Burghel, Heather, Mann, Jake, Lowes, David, Wilson, Erica, Droop, Alastair, Randerson-Moor, Juliette, Coletta, P Louise, Hull, Mark A
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 10.05.2016
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - blood; Chemokine CCL2 - blood; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Disease-Free Survival; Eicosapentaenoic Acid - therapeutic use; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Male; Mice; Mice, Inbred C57BL; Research Paper; Treatment Outcome; colorectal cancer; eicosapentaenoic acid and biomarker; prognosis; molecular pharmacology
• DOI: 10.18632/oncotarget.8579
• ISSN: 1949-2553

The mechanism of the anti-colorectal cancer (CRC) activity of the omega-3 fatty acid eicosapentaenoic acid (EPA) is not understood. We tested the hypothesis that EPA reduces expression of chemokine C-C motif ligand 2 (CCL2), a pro-inflammatory chemokine with known roles in metastasis.We measured CCL2 in clinical samples from a randomized trial of EPA in patients undergoing liver surgery for CRC liver metastasis (LM) and preclinical models. Genome-wide transcriptional profiling of tumors from EPA-treated patients was performed.EPA decreased CCL2 synthesis by CRC cells in a dose-dependent manner. CCL2 was localized to malignant epithelial cells in human CRCLM. EPA did not reduce CCL2 content in human or mouse tumors compare to control. However, EPA treatment was associated with decreased plasma CCL2 levels compared with controls (P=0.04). Reduction in plasma CCL2 following EPA treatment predicted improved disease-free survival (HR 0.32; P=0.003). Lack of 'CCL2 response' was associated with a specific CRCLM gene expression signature.In conclusion, reduction in plasma CCL2 in patients with CRCLM treated with EPA predicts better clinical outcome and a specific tumor gene expression profile. Further work is needed to validate CCL2 as a therapeutic response biomarker for omega-3 fatty acid treatment of CRC patients.